A Phase 2/3 interventional study of Abemaciclib and Placebo in Prostate Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 112 sites in 11 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Eli Lilly and Company · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing abemaciclib in Prostatic Neoplasms — 1 open to participants now, 3 under way, 2 of them phase 3. abemaciclib · Prostatic Neoplasms.
Among the 10 studies testing abemaciclib in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2018, is the only one in phase 2/3, and was the 1st registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →1 of the 10 studies testing abemaciclib in Prostatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Vadim S Koshkin · Sites in United States
Ages 18+
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 2
First in 2018; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 393 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 15 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 7 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
20 studies in Prostatic Neoplasms by Eli Lilly and Company: 2 open now, 8 under way, 3 of them phase 3. Of 11 finished, 10 (91%) have results posted.
Among the 20 studies in Prostatic Neoplasms by Eli Lilly and Company, this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2018, is the only one in phase 2/3, and was the 11th registered.
Eli Lilly and Company’s Prostatic Neoplasms studies by the year they started, since 2007.
1 of the studies testing abemaciclib in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05113537Vadim S KoshkinAbemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing abemaciclib in Prostatic Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 20 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Progressive disease at study entry demonstrated during continuous androgen-deprivation therapy (ADT)/post orchiectomy defined as one or more of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 milligrams (mg) abemaciclib twice daily (BID) in combination with standard doses of 1000 mg abiraterone acetate once daily and 5 mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.
Drug: Abemaciclib · Drug: Abiraterone acetate · Drug: Prednisone
Participants received placebo BID in combination with standard doses of 1000 mg abiraterone acetate once daily and 5 mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.
Drug: Placebo · Drug: Abiraterone acetate · Drug: Prednisone
Administered orally.
Also known as: LY2835219
Administered orally.
Administered orally.
Administered orally.
Radiographic Progression Free Survival (rPFS)
The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.
Time frame: From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (Up to 60 Months)
Time to Prostate-Specific Antigen (PSA) Progression
The PSA progression is defined as a greater than or equal to (\>=) 25 percentage (%) increase and an absolute increase of \>=2 nanogram/milliliter (ng/mL) above the nadir (or baseline value if baseline is the smallest on study), which is confirmed by a second value obtained 3 or more weeks later.
Time frame: From Date of Randomization to the Date of the First Observation of PSA Progression (Up to 60 Months)
Radiographic Progression Free Survival (rPFS) Determined by Blinded Independent Central Review
rPFS is defined as the time from the date of randomization to the earliest date of radiographic disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first.
Time frame: From Date of Randomization Until Radiographic Disease Progression or Death from Any Cause (Up to 60 Months)
Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)
ORR is a summary measure of best overall response (BOR) as defined by RECIST 1.1 for soft tissue per investigator assessment. BOR is derived from time point responses. All time point responses observed while on study treatment and during the short-term follow-up period (but before the initiation of post-discontinuation systemic anticancer therapy) will be included in the derivation. Each patient's BOR will be categorized as complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or not evaluable (NE). A BOR of CR or PR will require confirmation, but sensitivity analyses of response-based endpoints may be performed where confirmation of a BOR of CR or PR is not required.
Time frame: Baseline to Radiographic Disease Progression (Up to 60 Months)
Duration of Response (DOR)
The DoR time is defined only for responders (participants with a soft tissue BOR of CR or PR) in the measurable disease population. It is measured from the date of first evidence of soft tissue CR or PR to the earliest date of investigator determined radiographic disease progression or death from any cause, whichever is earlier.
Time frame: Date of First Documented CR or PR to Date of Radiographic Disease Progression or Death from Any Cause (Up to 60 Months)
Overall Survival (OS)
The OS time is measured from the date of randomization to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.
Time frame: From Date of Randomization to Date of Death Due to Any Cause (Up to 60 Months)
Time to Symptomatic Progression
Time to symptomatic progression is defined as the time from randomization to any of the following (whichever occurs earlier): 1. Symptomatic Skeletal Event (SSE), defined as symptomatic fracture, surgery or radiation to bone, or spinal cord compression. 2. Pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anti-cancer therapy. 3. Development of clinically significant symptoms due to loco-regional tumor progression requiring surgical intervention or radiation therapy.
Time frame: From Randomization to the Date of the First Documented Symptomatic Progression (Up to 60 Months)
Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib
PK: Mean steady state exposure of abemaciclib.
Time frame: Cycle (C) 1 Day (D) 1: Predose, 30 min post-dose; C1 D15, C2 D1, C2 D15, C3 D1: Post dose (28 Days Cycle)
PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567
PK: Mean steady state exposure of abemaciclib metabolite LSN2839567.
Time frame: C1 D1: Predose, 30 min post-dose; C1 D15, C2 D1, C2 D15, C3 D1: Post dose (28 Days Cycle)
PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726
PK: Mean steady state exposure of abemaciclib metabolite LSN3106726.
Time frame: C1 D1: Predose, 30 min post-dose; C1 D15, C2 D1, C2 D15, C3 D1: Post dose (28 Days Cycle)
PK: Mean Steady State Exposure of Abiraterone Acetate
PK: Mean Steady State Exposure of Abiraterone Acetate.
Time frame: C1 D15, Post dose
Time to Worst Pain Progression
Time to Worst Pain Progression defined as the time from randomization to any of the following (whichever occurs earlier): For participants without opioid use at baseline (World Health Organization-Analgesic Ladder-WHO-AL ≤ 2):- Worst pain progression (an increase of 2 points from baseline on the Worst Pain Numeric Rating Scale (NRS) item on 2 consecutive evaluations), Initiation of weak or strong opioids (WHO-AL ≥ 3); For participants with weak or strong opioid use at baseline (WHO-AL ≥ 3): Worst pain progression (an increase of 2 points from baseline on the Worst Pain NRS item on 2 consecutive evaluations) without concurrent decreased opioid use (a decrease in WHO-AL of 1 or more) -Increased opioid use (an increase in WHO-AL of 1 or more).
Time frame: From Randomization Through Follow-up (Up to 60 months)
| Milestone | Abemaciclib | Placebo |
|---|---|---|
| Started | 206 | 187 |
| Received at least one dose of study drug | 206 | 185 |
| Completed | 131 | 121 |
| Not completed | 75 | 66 |
| Withdrew: Lost to follow-up | 7 | 0 |
| Withdrew: Withdrawal by subject | 17 | 15 |
| Withdrew: On study treatment | 51 | 51 |
The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.
| Months | Abemaciclib | Placebo |
|---|---|---|
| Radiographic Progression Free Survival (rPFS) | 21.96 (19.33 to 27.48) | 20.28 (16.47 to 24.36) |
The PSA progression is defined as a greater than or equal to (\>=) 25 percentage (%) increase and an absolute increase of \>=2 nanogram/milliliter (ng/mL) above the nadir (or baseline value if baseline is the smallest on study), which is confirmed by a second value obtained 3 or more weeks later.
| Months | Abemaciclib | Placebo |
|---|---|---|
| Time to Prostate-Specific Antigen (PSA) Progression | 22.19 (15.68 to 33.17) | 16.60 (12.03 to 20.28) |
rPFS is defined as the time from the date of randomization to the earliest date of radiographic disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first.
| Months | Abemaciclib | Placebo |
|---|---|---|
| Radiographic Progression Free Survival (rPFS) Determined by Blinded Independent Central Review | 24.89 (21.96 to NA) | 22.88 (19.36 to 31.50) |
ORR is a summary measure of best overall response (BOR) as defined by RECIST 1.1 for soft tissue per investigator assessment. BOR is derived from time point responses. All time point responses observed while on study treatment and during the short-term follow-up period (but before the initiation of post-discontinuation systemic anticancer therapy) will be included in the derivation. Each patient's BOR will be categorized as complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or not evaluable (NE). A BOR of CR or PR will require confirmation, but sensitivity analyses of response-based endpoints may be performed where confirmation of a BOR of CR or PR is not required.
| percentage of participants | Abemaciclib | Placebo |
|---|---|---|
| Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR) | 45.2 (34.6 to 55.9) | 54.8 (43.4 to 66.2) |
The DoR time is defined only for responders (participants with a soft tissue BOR of CR or PR) in the measurable disease population. It is measured from the date of first evidence of soft tissue CR or PR to the earliest date of investigator determined radiographic disease progression or death from any cause, whichever is earlier.
| Months | Abemaciclib | Placebo |
|---|---|---|
| Duration of Response (DOR) | 21.27 (16.60 to NA) | 15.68 (11.87 to 39.35) |
The OS time is measured from the date of randomization to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.
| Months | Abemaciclib | Placebo |
|---|---|---|
| Overall Survival (OS) | 38.01 (30.58 to 46.65) | 33.21 (29.52 to NA) |
Time to symptomatic progression is defined as the time from randomization to any of the following (whichever occurs earlier): 1. Symptomatic Skeletal Event (SSE), defined as symptomatic fracture, surgery or radiation to bone, or spinal cord compression. 2. Pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anti-cancer therapy. 3. Development of clinically significant symptoms due to loco-regional tumor progression requiring surgical intervention or radiation therapy.
| Months | Abemaciclib | Placebo |
|---|---|---|
| Time to Symptomatic Progression | 51.39 (27.98 to NA) | 35.74 (28.44 to NA) |
PK: Mean steady state exposure of abemaciclib.
| nanogram per milliliter (ng/mL) | Abemaciclib |
|---|---|
| C1 D1 | 4.79 ± 157 |
| C1 D15 | 289 ± 58.7 |
| C2 D1 | 253 ± 65.7 |
| C2 D15 | 252 ± 68.4 |
| C3 D1 | 270 ± 54.5 |
PK: Mean steady state exposure of abemaciclib metabolite LSN2839567.
| ng/mL | Abemaciclib |
|---|---|
| C1 D1 | 2.90 ± 87.4 |
| C1 D15 | 125 ± 50.4 |
| C2 D1 | 112 ± 50.1 |
| C2 D15 | 116 ± 51.0 |
| C3 D1 | 110 ± 62.2 |
PK: Mean steady state exposure of abemaciclib metabolite LSN3106726.
| ng/mL | Abemaciclib |
|---|---|
| C1 D1 | 2.80 ± 77.7 |
| C1 D15 | 195 ± 43.0 |
| C2 D1 | 174 ± 42.8 |
| C2 D15 | 174 ± 44.1 |
| C3 D1 | 176 ± 36.4 |
PK: Mean Steady State Exposure of Abiraterone Acetate.
| ng/mL | Abemaciclib | Placebo |
|---|---|---|
| PK: Mean Steady State Exposure of Abiraterone Acetate | 45.2 ± 175 | 40.0 ± 203 |
Time to Worst Pain Progression defined as the time from randomization to any of the following (whichever occurs earlier): For participants without opioid use at baseline (World Health Organization-Analgesic Ladder-WHO-AL ≤ 2):- Worst pain progression (an increase of 2 points from baseline on the Worst Pain Numeric Rating Scale (NRS) item on 2 consecutive evaluations), Initiation of weak or strong opioids (WHO-AL ≥ 3); For participants with weak or strong opioid use at baseline (WHO-AL ≥ 3): Worst pain progression (an increase of 2 points from baseline on the Worst Pain NRS item on 2 consecutive evaluations) without concurrent decreased opioid use (a decrease in WHO-AL of 1 or more) -Increased opioid use (an increase in WHO-AL of 1 or more).
| Months | Abemaciclib | Placebo |
|---|---|---|
| Time to Worst Pain Progression | 41.49 (19.40 to NA) | 24.79 (19.17 to 31.46) |
Collected over Baseline Up to 60 Months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abemaciclib | 81/206 (39.3%) | 89/206 (43.2%) | 204/206 (99%) |
| Placebo | 72/187 (38.5%) | 66/185 (35.7%) | 176/185 (95.1%) |
| Event | Abemaciclib | Placebo |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 9/206 | 1/185 |
| AnaemiaBlood and lymphatic system disorders | 6/206 | 3/185 |
| DiarrhoeaGastrointestinal disorders | 6/206 | 1/185 |
| PneumoniaInfections and infestations | 6/206 | 5/185 |
| Covid-19Infections and infestations | 4/206 | 0/185 |
| Covid-19 pneumoniaInfections and infestations | 4/206 | 1/185 |
| UrosepsisInfections and infestations | 4/206 | 0/185 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/206 | 2/185 |
| ColitisGastrointestinal disorders | 1/206 | 3/185 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/206 | 3/185 |
| Event | Abemaciclib | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 134/206 | 35/185 |
| FatigueGeneral disorders | 107/206 | 47/185 |
| AnaemiaBlood and lymphatic system disorders | 91/206 | 21/185 |
| NauseaGastrointestinal disorders | 73/206 | 27/185 |
| Blood creatinine increasedInvestigations | 58/206 | 1/185 |
| NeutropeniaBlood and lymphatic system disorders | 57/206 | 1/185 |
| Decreased appetiteMetabolism and nutrition disorders | 50/206 | 15/185 |
| VomitingGastrointestinal disorders | 48/206 | 17/185 |
| Alanine aminotransferase increasedInvestigations | 48/206 | 21/185 |
| Back painMusculoskeletal and connective tissue disorders | 36/206 | 42/185 |
All randomized participants.
| Age, Continuous(years) | Abemaciclib | Placebo | Total |
|---|---|---|---|
| Mean | 68.70 ± 8.57 | 69.60 ± 8.81 | 69.10 ± 8.69 |
| Sex: Female, Male(Participants) | Abemaciclib | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 206 | 187 | 393 |
| Ethnicity (NIH/OMB)(Participants) | Abemaciclib | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 7 | 20 |
| Not Hispanic or Latino | 186 | 174 | 360 |
| Unknown or Not Reported | 7 | 6 | 13 |
| Race (NIH/OMB)(Participants) | Abemaciclib | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 35 | 45 | 80 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 10 | 17 |
| White | 161 | 128 | 289 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 2 | 4 | 6 |
| Region of Enrollment(participants) | Abemaciclib | Placebo | Total |
|---|---|---|---|
| Australia | 17 | 18 | 35 |
| China | 4 | 9 | 13 |
| Denmark | 7 | 10 | 17 |
| France | 4 | 5 | 9 |
| Germany | 23 | 16 | 39 |
| Japan | 15 | 18 | 33 |
| Netherlands | 7 | 8 | 15 |
| Romania | 10 | 7 | 17 |
| South Korea | 14 | 17 | 31 |
| Spain | 45 | 30 | 75 |
| United Kingdom | 11 | 9 | 20 |
| United States | 49 | 40 | 89 |
Showing the first 100 of 112 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2018 to primary completion in Jan 2024, 61 months.
Results were first posted in Mar 2025, 1 year 2 months after primary completion.
Of 43 phase 2/3 interventional studies under Prostatic Neoplasms, half reached primary completion within 115 months of starting (the median), counting those still running; a quarter within 32. This study's 61 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib